Pricing Log in Create free account
Friday 6 November 2026 Export CLDX’s income statement to Excel — free account

Celldex Therapeutics, Inc.

CLDX Healthcare Biotechnology

Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.

Revenue
−96.8%
EPS
−10.6%
Free cash flow
−35.5%

Quarter to June 2026, against a year earlier

29.95 1.68 +5.94%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−7.2×
Dividend yield
—
F-score
2/9
Altman Z
14.41
Beneish M
6.76
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Celldex Therapeutics, Inc. (CLDX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Celldex Therapeutics, Inc. (CLDX) trades at a EV/Sales of 1,691×. Over the past ten years it has ranged from −10.7× (March 2020) to 3,131× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 474× 267.62%
FY2024 129× (42.41%)
FY2023 224× (69.56%)
FY2022 735× 173.10%
FY2021 269× 507.80%
FY2020 44.3× —
FY2019 −7.9× —
FY2018 −6.1× —
FY2017 19.0× (28.88%)
FY2016 26.8× (88.13%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 2,459× 130.76%
Mar 2026 1,066× 125.07%
Dec 2025 474× 279.29%
Jun 2025 125× 76.79%
41 more quarters

Against its own ten years

Low −10.7× High 3,131×
Ten-year median 131×
Current reading's percentile 96

EV/Sales against peers

Company EV/Sales
PHVS Pharvaris N.V. compare n/m
VERA Vera Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
AUPH Aurinia Pharmaceuticals Inc compare 5.3×
ADMA ADMA Biologics Inc compare 5.8×
VCEL Vericel Corporation compare 7.6×
PVLA Palvella Therapeutics, Inc. compare 48.1×
IMNM Immunome, Inc. compare 121×
CLDX Celldex Therapeutics, Inc. 1,691×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on CLDX